M&A Deal Summary

Amryt Pharma Acquires Aegerion Pharmaceuticals

On May 21, 2019, Amryt Pharma acquired life science company Aegerion Pharmaceuticals from Novelion Therapeutics

Acquisition Highlights
  • This is Amryt Pharma’s 3rd transaction in the Life Science sector.
  • This is Amryt Pharma’s 1st transaction in the United States.
  • This is Amryt Pharma’s 1st transaction in Massachusetts.

M&A Deal Summary
Date 2019-05-21
Target Aegerion Pharmaceuticals
Sector Life Science
Buyer(s) Amryt Pharma
Sellers(s) Novelion Therapeutics
Deal Type Add-on Acquisition
Advisor(s) Moelis & Co. (Financial)

Target

Aegerion Pharmaceuticals

Cambridge, Massachusetts, United States
Aegerion Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of pharmaceutical products to treat cardiovascular and metabolic diseases. Aegerion Pharmaceuticals, Inc. was formed in 2005 and is headquartered in Cambridge, Massachusetts.

Search 201,429 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Amryt Pharma

Dublin, Ireland
Category Company
Sector Life Science
Employees182
Revenue 182M GBP (2020)
DESCRIPTION

Amryt Pharma is a pharmaceutical company focused on developing and delivering innovative new treatments to help improve the lives of patients with rare and orphan diseases. Amryt Pharma is based in Dublin, Ireland.

DEAL STATS #
Overall 3 of 4
Sector (Life Science) 3 of 4
Type (Add-on Acquisition) 3 of 4
State (Massachusetts) 1 of 2
Country (United States) 1 of 2
Year (2019) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-02-22 SomPharmaceuticals S.A

Épalinges, Switzerland

SomPharmaceuticals S.A is a biopharmaceutical company focused on developing novel somatostatin analogue ("SSA") peptide medicines for patients with rare neuroendocrine diseases with high unmet need.

Buy £30M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2021-05-05 Chiasma

Needham, Massachusetts, United States

Chiasma is a commercial-stage biopharmaceutical company focused on developing and commercializing oral therapies to improve the lives of patients who face challenges associated with their existing treatments for rare and serious chronic diseases. Chiasma was incorporated in 2001 and is headquartered in Needham, Massachusetts.

Buy -

Seller(S) 1

SELLER

Novelion Therapeutics

Vancouver, British Columbia, United Kingdom
Category Company
Founded 1981
Sector Medical Products
Revenue 130M USD (2018)
DESCRIPTION

Novelion Therapeutics is a biotechnology company dedicated to the development and commercialization of innovative ocular products that address the unmet medical needs of patients and clinicians worldwide. We are focused on developing our synthetic retinoid program for the treatment of certain inherited retinal diseases. Novelion Therapeutics was founded in 1981 and is based in Vancouver, Canada.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Massachusetts) 1 of 1
Country (United States) 1 of 1
Year (2019) 1 of 1
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2016-06-15 Aegerion Pharmaceuticals

Cambridge, Massachusetts, United States

Aegerion Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development and commercialization of pharmaceutical products to treat cardiovascular and metabolic diseases. Aegerion Pharmaceuticals, Inc. was formed in 2005 and is headquartered in Cambridge, Massachusetts.

Buy -
Mergr

Product

Company

Legal